Natural birth may strengthen the immune system Health Researchers from the University of Copenhagen have uncovered new knowledge about the immune system in a mouse study, which indicates that natural birth improves the immune system of the pups. A number of studies suggest that children delivered by Caesarean section have a different intestinal flora than children delivered by natural birth.
PMCBa clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box Rtoday announced that the world class team of scientists, physicians and academics that make up its international Diabetes Consortium is now complete with the addition of the final two members, Dr.
Thomas Stratmann and Dr. Stratmann has extensive experience in using a diabetes mouse model of Type 1 diabetes in which the disease develops rapidly in contrast to other mouse models where the disease only develops after several weeks. He will perform specially designed preclinical studies to determine the minimum dose of encapsulated Melligen cells that will normalize blood glucose levels in diabetic rats as well as pigs, which are an important model for mimicking the dosing that will be required for human patients.
PharmaCyte Biotech has the exclusive worldwide rights to use the Melligen cells to treat diabetes. Melligen cells are genetically engineered from human liver cells and have been shown to secrete insulin in response to the concentrations of glucose blood sugar in their environment.
When Melligen cells were transplanted into diabetic mice whose immune systems were essentially not functioning, the blood glucose levels of the mice became normal.
This observation illustrates that Melligen cells Axel kornerup reverse the diabetic condition. We feel that the scientists, physicians and academics that make up our Consortium are of the highest caliber and have already proven that they can work in concert as the development of our diabetes treatment progresses.
We firmly believe that, although the members within the Consortium are diverse in terms of their geographic location and expertise, their talents and knowledge are most complementary. Members of the Diabetes Consortium have all agreed to bring their expertise to the Consortium and work in concert Axel kornerup develop a treatment for diabetes.
The members of the Consortium and their expected contributions are: Lohr is exceedingly familiar with the Cell-in-a-Box R technology having Axel kornerup as Principal Investigator for the clinical trials in pancreatic cancer that employed the technology together with the cancer chemotherapy drug ifosfamide.
In addition to pancreatic cancer, Dr. Lohr has a specialty in diabetes and its treatment and believes that the Cell-in-a-Box R technology will provide a platform upon which effective treatments for both pancreatic cancer and diabetes can be built.
Brian Salmons and Dr. John Dangerfield of Austrianova will all play significant scientific advisory roles. Both are also consultants to PharmaCyte Biotech.
Dangerfield, the COO of Austrianova, is intimately involved in dealing with the Cell-in-a-Box R encapsulation process on a daily basis.
All three will be responsible for the preparation of cells and their encapsulation as required for preclinical studies and ultimately be involved in human clinical trials as the Diabetes Consortium develops its diabetes treatment.
Ann Simpson and Dr. Simpson serves as a consultant to PharmaCyte Biotech. Simpson and her fellow scientists at UTS will be responsible for performing laboratory and animal studies on the Melligen Cells both before and after encapsulation that will be necessary for defining the parameters under which the Melligen Cells produce insulin.
Constantine Konstantoulas and Mag Helga Petznek veterinarian of VetMed will be responsible for conducting animal studies with encapsulated Melligen Cells that will test the potential of these cells to produce tumors, define the biocompatibility of the encapsulated Melligen Cells and test the ability of the encapsulated cells to produce insulin in a mouse model in which Type 1 diabetes has been induced by the introduction of a virus.
Konstantoulas will coordinate the day-to-day activities of these tests, and Prof. Gunzburg will oversee all of the studies done at VetMed.
The studies at this institution are already underway. Thomas Stratmann, Associate Professor at the Department of Physiology and Immunology in the Faculty of Biology at the University of Barcelona in Spain, has extensive experience in using a diabetes mouse model of Type 1 diabetes in which the disease develops rapidly.
Stratmann has two other mouse models of Type 1 diabetes in his laboratory. Axel Kornerup Hansen, Professor in the Department of Veterinary Disease Biology at the University of Copenhagen in Denmark, will perform preclinical studies to determine the minimum dose of encapsulated Melligen Cells that will normalize blood glucose levels in diabetic rats.
Hansen will perform the same tests on pigs that have been made diabetic by injecting them with a drug known as streptozotocin. This drug destroys the ability of the pancreas to produce insulin and thus results in diabetes.
Rudiger Wanke, and Dr. Eckhard Wolf, of the Laboratory of Functional Genome Analysis, Gene Center, at the Ludwig-Maximillians University in Munich, Germany, have developed unique transgenic mouse and pig models in which the mice and pigs exhibit diabetes from birth without the use of diabetes-inducing drugs.
|Available courses||In part due to a heightened awareness among the general public, and along with a global community of passionate ethologists and investigators concerned with animal welfare, this year the European Union EU legislated that, in law, animals are sentient beings.|
Waggoner, JD and Dr. Crabtree, the CEO and the COO, respectively, of PharmaCyte Biotech will be responsible for providing overall coordination and management of the Diabetes Consortium as well as and funding for the activities within the Consortium. PharmaCyte Biotech will also provide scientific direction and support when it is required.
About PharmaCyte Biotech PharmaCyte Biotech is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box R.
This unique and patented technology will be used as a platform upon which treatments for several types of cancer, including advanced, inoperable pancreatic cancer, and diabetes are being built.
These capsules are placed as close to the cancerous tumor as possible to enable the delivery of the highest levels of the cancer-killing drug at the source of the cancer. PharmaCyte Biotech is also working towards improving the quality of life for patients with advanced pancreatic cancer and on treatments for other types of solid cancerous tumors.
In addition, PharmaCyte Biotech is developing treatments for cancer based upon chemical constituents of the Cannabis plant, known as cannabinoids. In doing so, PharmaCyte Biotech is examining ways to exploit the benefits of Cell-in-a-Box R technology in optimizing the anticancer effectiveness of cannabinoids, while minimizing or outright eliminating the debilitating side effects usually associated with cancer treatments.(), Hansen, Axel Kornerup.
Print version: Handbook of laboratory animal bacteriology. ( / ), Hansen, Axel Kornerup. Editions & Formats Found Availability. Libraries Worldwide. List Record Limit Reached. Your list is full. Please remove records from your list or clear your list to add more records. Axel Kornerup Hansen is Professor, Department of Veterinary Disease Biology at University of Copenhagen.
View Axel Kornerup Hansen’s professional profile on Relationship Science, the database of . Dec 21, · Axel Kornerup Hansen, Camilla Hartmann Friis Hansen, Lukasz Krych, and Dennis Sandris Nielsen Axel Kornerup Hansen, Camilla Hartmann Friis Hansen, Section of Experimental Animal Models, Department of Veterinary Disease Biology, University of Copenhagen, Frederiksberg, Denmark.
November 6th, - By Axel Kornerup Hansen Dennis Sandris Nielsen Features Examines the range of bacteria that may interfere with animal modelling for human disease Provides practical. Registered Charity No: The 33rd Annual Scientific Meeting of the. British Society of Toxicological Pathology (BSTP) Pathology of Mouse Models of Disease.
Faculty. Professor Axel Kornerup Hansen. Professor Axel Kornerup Hansen, Department of Veterinary Disease Biology, University of Copenhagen is one of the initiators and the programme manager of the LabVet Europe programme.